Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy AnaptysBio (ANAB) stocks in Canada

Learn how to easily invest in AnaptysBio stocks.

AnaptysBio is a biotechnology business based in the US. AnaptysBio stocks (ANAB.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $25.99 – an increase of 0.96% over the previous week. AnaptysBio employs 94 staff and has a trailing 12-month revenue of around $122.2 million.

How to buy shares in AnaptysBio

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ANAB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

AnaptysBio stock price (NASDAQ:ANAB)

Use our graph to track the performance of ANAB stocks over time.

AnaptysBio shares at a glance

Information last updated 2022-01-25.
Latest market close$31.41
52-week range$17.72 - $37.89
50-day moving average $33.01
200-day moving average $27.61
Wall St. target price$36.86
PE ratio 106.1438
Dividend yield N/A (0%)
Earnings per share (TTM) $0.31

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy AnaptysBio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

AnaptysBio price performance over time

Historical closes compared with the close of $31.41 from 2022-01-26

1 week (2022-01-21) 1.36%
1 month (2021-12-24) N/A
3 months (2021-10-28) -4.56%
6 months (2021-07-28) 21.32%
1 year (2021-01-28) 29.63%
2 years (2020-01-28) 114.26%
3 years (2019-01-28) 63
5 years (2017-01-27) 79.18%

Is AnaptysBio under- or over-valued?

Valuing AnaptysBio stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AnaptysBio's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

AnaptysBio's P/E ratio

AnaptysBio's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 106x. In other words, AnaptysBio shares trade at around 106x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

AnaptysBio's EBITDA

AnaptysBio's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $8.3 million.

The EBITDA is a measure of a AnaptysBio's overall financial performance and is widely used to measure a its profitability.

AnaptysBio financials

Revenue TTM $122.2 million
Operating margin TTM 6.29%
Gross profit TTM $-5,025,000
Return on assets TTM 1.19%
Return on equity TTM 2.26%
Profit margin 6.87%
Book value $13.97
Market capitalisation $897.9 million

TTM: trailing 12 months

AnaptysBio share dividends

We're not expecting AnaptysBio to pay a dividend over the next 12 months.

AnaptysBio share price volatility

Over the last 12 months, AnaptysBio's shares have ranged in value from as little as $17.72 up to $37.89. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AnaptysBio's is 0.1536. This would suggest that AnaptysBio's shares are less volatile than average (for this exchange).

AnaptysBio overview

AnaptysBio, Inc. , a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. It also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. AnaptysBio, Inc. has a collaboration and license agreement with TESARO, Inc. and Celgene Corporation; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation.

Stocks similar to AnaptysBio

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site